CClinicalTrials.gg
TerminatedNCT03176394Updated Nov 7, 2023

Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)

An interventional study of BLASTX Gel and McKesson Jelly in Urinary Tract Infections, sponsored by Next Science TM. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Next Science TM · Not applicable, Interventional, and Basic science

Why this study was terminated
trouble with enrollment
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. Subjects will be randomized 1:1 to either the biofilm disrupting gel (BLASTX) or SOC (McKesson Jelly) lubricated catheters. Urine and/or catheter DNA analysis will be obtained at catheter insertion, 2, 5, 7 and 14 days after catheterization.

Read the detailed description

This is a 2-week, single-site, randomized controlled pilot study in adults requiring short-term \< 14 days catheterization. Subjects will be randomized 1:1 to either the BLASTX or SOC lubricated catheters.

Urine and catheter DNA analysis will be obtained at catheter insertion, 2 to 3 days after catheterization and at 5, 7 and 14 days if catheterization was indicated for either duration.

Informed consent discussion will be completed, ICF will be signed, prior to any study procedures.

Subjects will be included only if all of the inclusion criteria and none of the exclusion criteria have been met.

After randomization, subjects will be followed, urine samples will be collected at each scheduled visit and the catheters will be collected upon removal.

02

Conditions studied

  • Urinary Tract Infections

Keywords

  • Foley, UTI, Biofilm, DNA
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. 18 years or older
  2. Absence of symptomatic UTI
  3. Absence of upper/lower tract obstructions
  4. No known allergies to the study products
  5. Willing to comply with all study procedures and available for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. 17 years or younger
  2. Symptomatic UTI
  3. Presence of upper/lower tract obstructions
  4. Known allergic reaction to the study products
  5. Unable to provide signed and dated informed consent form
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    BLASTX Lubricated Catheter

    Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.

    Device: BLASTX Gel

  • Placebo comparator
    McKesson Jelly Lubricated Catheter

    Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.

    Device: McKesson Jelly

Interventions

  • DeviceBLASTX Gel

    Foley Catheter lubricated with BLASTX Gel

  • DeviceMcKesson Jelly

    Foley Catheter lubricated with McKesson Jelly

05

What researchers measure

Primary outcomes

  1. Urine microorganisms DNA analysis

    Change in microorganisms in the test group compared to the control group.

    Time frame: Up to 14 days

  2. Catheter microorganisms DNA analysis

    Change in microorganisms in the test group compared to the control group.

    Time frame: Up to 14 days

Secondary outcomes

  1. Incidence of Urinary Tract Infections (UTIs)

    Number of instances of clinically symptomatic UTI in the test versus the control group

    Time frame: 14 days

06

Study locations

1 site
  • American Medical Research Institute
    Celebration, Florida 34747, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03176394
Lead sponsor
Next Science TM
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
May 24, 2017
Primary completion
Oct 18, 2019
Completion
Oct 18, 2019
Last update
Nov 7, 2023

Study contacts

Susan Greco, MD
study director · Next Science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion